Tectonic Therapeutic, Inc. (TECX) stock
TECXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$21.04+0.96 (+4.78%)
Close on Nov 18, 2026Market cap $411.32MP/E –Yield 0.00%
Tectonic Therapeutic free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Tectonic Therapeutic's free cash flow for the twelve months ending Jun 30, 2026 was -$72.42M. For fiscal 2025 it was -$60.29M. The highest annual figure on record is -$16.77M in fiscal 2017.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$60.29M | – |
| FY2024 | Dec 31, 2024 | -$59.24M | – |
| FY2023 | Dec 31, 2023 | -$40.96M | – |
| FY2022 | Dec 31, 2022 | -$97.48M | – |
| FY2021 | Dec 31, 2021 | -$100.49M | – |
| FY2020 | Dec 31, 2020 | -$99.98M | – |
| FY2019 | Dec 31, 2019 | -$69.25M | – |
| FY2018 | Dec 31, 2018 | -$39.48M | – |
| FY2017 | Dec 31, 2017 | -$16.77M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$21.53M | – |
| Q1 FY2026 | Mar 31, 2026 | -$18.43M | – |
| Q4 FY2025 | Dec 31, 2025 | -$14.46M | – |
| Q3 FY2025 | Sep 30, 2025 | -$18.00M | – |
| Q2 FY2025 | Jun 30, 2025 | -$14.72M | – |
| Q1 FY2025 | Mar 31, 2025 | -$13.11M | – |
| Q4 FY2024 | Dec 31, 2024 | -$16.82M | – |
| Q3 FY2024 | Sep 30, 2024 | -$19.76M | – |
| Q2 FY2024 | Jun 30, 2024 | -$13.38M | – |
| Q1 FY2024 | Mar 31, 2024 | -$9.28M | – |
| Q4 FY2023 | Dec 31, 2023 | -$11.71M | – |
| Q3 FY2023 | Sep 30, 2023 | -$8.49M | – |
| Q2 FY2023 | Jun 30, 2023 | -$473.00K | – |
| Q1 FY2023 | Mar 31, 2023 | -$20.29M | – |
| Q4 FY2022 | Dec 31, 2022 | -$23.67M | – |
| Q3 FY2022 | Sep 30, 2022 | -$16.50M | – |
| Q2 FY2022 | Jun 30, 2022 | -$29.26M | – |
| Q1 FY2022 | Mar 31, 2022 | -$28.05M | – |
| Q4 FY2021 | Dec 31, 2021 | -$26.75M | – |
| Q3 FY2021 | Sep 30, 2021 | -$25.09M | – |
| Q2 FY2021 | Jun 30, 2021 | -$21.19M | – |
| Q1 FY2021 | Mar 31, 2021 | -$27.45M | – |
| Q4 FY2020 | Dec 31, 2020 | -$30.57M | – |
| Q3 FY2020 | Sep 30, 2020 | -$24.89M | – |
| Q2 FY2020 | Jun 30, 2020 | -$21.51M | – |
| Q1 FY2020 | Mar 31, 2020 | -$23.01M | – |
| Q4 FY2019 | Dec 31, 2019 | -$19.35M | – |
| Q3 FY2019 | Sep 30, 2019 | -$13.46M | – |
| Q2 FY2019 | Jun 30, 2019 | -$18.37M | – |
| Q1 FY2019 | Mar 31, 2019 | -$18.08M | – |
| Q4 FY2018 | Dec 31, 2018 | -$11.93M | – |
| Q3 FY2018 | Sep 30, 2018 | -$12.90M | – |
| Q2 FY2018 | Jun 30, 2018 | -$8.41M | – |
| Q1 FY2018 | Mar 31, 2018 | -$6.24M | – |
| Q4 FY2017 | Dec 31, 2017 | -$8.91M | – |
| Q3 FY2017 | Sep 30, 2017 | -$3.34M | – |
See a number that looks wrong?